Abstract
Objective:
To provide an analysis and a guide tool in using TNFα-antagonists in the current clinical practice.
Methods:
Review of the literature on the differences among the three TNFα-antagonists in terms of molecular structure, mechanism of action, pharmacokinetics, effects on the immune and neuroendocrine systems, and therapeutic indications.
Results and conclusions:
Unfortunately, results of direct comparison studies are lacking. One could obviate this problem by performing statistical-mathematical extrapolations, but there are very few and very small-sized published experimental evidences.
Publication types
-
English Abstract
-
Introductory Journal Article
MeSH terms
-
Adalimumab
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / pharmacology
-
Antirheumatic Agents / therapeutic use*
-
Etanercept
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / pharmacology
-
Immunoglobulin G / therapeutic use*
-
Infliximab
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Receptors, Tumor Necrosis Factor, Type II / antagonists & inhibitors
-
Rheumatic Diseases / drug therapy
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Receptors, Tumor Necrosis Factor, Type II
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Adalimumab
-
Etanercept